Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 5/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766663 | 0.89 | QPCT (0.46) | QPCTGPR84MAPK14 | |
| SCHEMBL6763933 | 0.81 | HDAC6 (0.55) | PIM1PIM2PIM3QPCT | |
| SCHEMBL6769464 | 0.78 | PIM1 (0.33) | PIM1PIM2PIM3QPCTGPR84 | |
| SCHEMBL6770005 | 0.78 | PARP1 (0.56) | PIM1PIM3QPCT | |
| SCHEMBL8622177 | 0.77 | ACVR1 (0.46) | PIM1PIM3 | |
| SCHEMBL6766667 | 0.76 | PARP1 (0.56) | PIM1QPCTGPR84MAPK14 | |
| SCHEMBL1507612 | 0.73 | PARP1 (0.54) | PIM1 | |
| SCHEMBL25195476 | 0.71 | TLR8 (0.46) | PIM1PIM2PIM3GPR84TLR8 | |
| SCHEMBL8181410 | 0.70 | TLR8 (0.56) | PIM1PIM2PIM3GPR84TLR8 | |
| SCHEMBL6773423 | 0.69 | ACVR1 (0.33) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | PIM1 401/4885PIM2 383/4885PIM3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.